{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"106-983-561-568-063","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"106-983-561-568-063","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8893,"type":"PATENT","title":"Imperial College Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7925,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8215,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and Owners = \"Imperial College\", \"Imperial Coll* Sci* Tech* Medi*\", \"Imperial Innovations\", \"Imper* Colle* innova*\", \"Imperi* Innova*\",\"Imp* Col* Inno*\", \"Imperial College Of Science Technology\", \"Imperial Innovations Limited\", \" Imperial Innovations Ltd\", \"Imperial College Innovations Limited\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple families.
Add to collection
Total patents: 6345
Search applicants and Owners = \"Imperial College\", \"Imperial Coll* Sci* Tech* Medi*\", \"Imperial Innovations\", \"Imper* Colle* innova*\", \"Imperi* Innova*\",\"Imp* Col* Inno*\", \"Imperial College Of Science Technology\", \"Imperial Innovations Limited\", \" Imperial Innovations Ltd\", \"Imperial College Innovations Limited\".
Select more for logical variants
Add to collection
Select all the results in the collection and expand by simple families.
Add to collection
Total patents: 6345
Xaa1 Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr10 Ser11 Lys12 Tyr13 Leu14
Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ile36 Ala37;wherein:
Xaa1 is His1 or D-His1,
Xaa2 is Ser2 or Ala2,
Xaa3 is Gln3 or Asp3;
Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Gln16 Glu17 Leul1 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
or Asp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22 Val23 Gln24;
Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Met27 Asn28 Thr29 Lys30 Arg31 Asn32,
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32,
or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32or a peptide as set out above in which residue Asn34 is replaced with Asp34; or a peptide as set out above in which Xaa3 is Glu3; with the proviso that if Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is Asp15 Ser16 Arg17 Arg18 Ala19 Gln20 Asp21 Phe22 Val23 Gln24, then Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is not Met27 Asn28 Thr29 Lys30 Arg31 Asn32 (SEQ ID NO: 356)."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in claim 1, wherein Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 is:
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24,
Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24,
or Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24 (SEQ ID NO: 359)."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 2, wherein Xaa1 Xaa2 Xaa3 is His1 Ser2 Gln3, or. D-His1 Ser2 Gln3, or D-His1 Ala2 Gln3, or D-His1 Ala2 Asp3 (SEQ ID NO: 360)."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 3, wherein Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 is:
Lys27 Asn28 Ala29 Gly30 Pro31 Ser32,
or Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 (SEQ ID NO: 361)."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in claim 1 having an amino acid sequence selected from the group consisting of:"],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any one of claims 1 to 5, wherein the peptide has an additional extension moiety of sequence -A-B-C, wherein:
A is absent or 1, 2, 3 or 4 Ala residues or 1, 2, 3 or 4 Glu residues
B is absent or 1, 2, 3 or 4 Ala residues or 1, 2, 3 or 4 Glu residues provided that A and B do not both comprise Ala residues, and that A and B do not both comprise Glu residues; and
C is Lys, or Lys with an acid selected from capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid, attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in claim 6, wherein A or B or both A and B are absent."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in claim 6, wherein A is one Glu residue, and B is one Ala residue."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 6 to 8, wherein C is a Lys residue."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 6 to 8, wherein:
- C is a Lys residue with lauric acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with myristic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with palmitic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with stearic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with arachidic acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond.
- C is a Lys residue with capric acid attached via its -COOH group to the -NH2 group of the Lys side chain by means of a peptide bond."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A peptide according to claim 6 having a structure sequence selected from the group consisting of:"],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A peptide according to claim 1 having a structure sequence selected from the group consisting of:"],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A peptide according to claim 1 having a structure sequence selected from the group comprising:"],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising a peptide as claimed in any one of claims 1 to 13 and one or more pharmaceutically acceptable carriers."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition as claimed in claim 14 which is for peripheral administration."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition as claimed in claim 14 or 15 which is for administration subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["Use of a peptide as claimed in any one of claims 1 to 13 for the manufacture of a medicament for the prevention or treatment of obesity."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["Use of a peptide as claimed in any one of claims 1 to 13 for the manufacture of a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["Use of a peptide as claimed in any of claims 1 to 13 for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The use as claimed in claim any one of claims 17 to 19, wherein the peptide is administered peripherally."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The use as claimed in claim any one of claims 17 to 20, wherein the peptide is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 13 for use as a medicament."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 13 for use as a medicament for the prevention or treatment of obesity."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 13 for use as a medicament for the prevention or treatment of diabetes or of a co-morbidity of obesity."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any of claims 1 to 13 for use as a medicament for reducing appetite in a subject, reducing food intake in a subject or reducing calorie intake in a subject, reducing body weight in a subject, reducing body weight gain in a subject or increasing energy expenditure in a subject."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any one of claims 22 to 25, wherein the peptide composition is administered peripherally."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["A peptide as claimed in any one of claims 22 to 26, wherein the peptide is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["A method of causing weight loss or preventing weight gain for cosmetic purposes comprising administering to the subject a peptide according to any of claims 1 to 13 or a pharmaceutical composition according to claim 14 to 16."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28, wherein the peptide or pharmaceutical composition is administered peripherally."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 28 or 29, wherein the peptide or pharmaceutical composition is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally, transmucosally, orally, bucally, sublingually or via the lungs."],"number":30,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}